Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer
Sichuan University · State Key Laboratory of Biotherapy · +6 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
527
total citations
- FWCI
- 28.42
- Percentile
- 100%
- References
- 47
Citations per year
Authors
38Topics & keywords
Topics
Keywords
- CRISPR
- Clinical endpoint
- Medicine
- Genome editing
- Adverse effect
- Lung cancer
- Electroporation
- Clinical trial
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.